Under the terms of the agreement, Myriad will assess HRD status in patients who have been treated with PM1183 in PharmaMar's Phase II clinical study. Utilizing this information, Myriad and PharmaMar will hope to garner more information surrounding the role of HRD status in PM1183 response.
PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first antitumour drug. Yondelis ® is currently approved for soft tissue sarcoma (STS) in 42 countries outside the EEA, and for platinum-sensitive relapsed ovarian cancer (ROC) in 31 of those countries plus Brazil. Yondelis ® is approved for STS and platinum-sensitive ROC in all 30 countries of the EEA. Yondelis ® is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has four other compounds in clinical development: Aplidin ®, PM01183, Zalypsis ® and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D program. For more information, please visit the Company's website: www.pharmamar.com
About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts